A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of F-652 in Subjects With COVID-19 Pneumonia
Latest Information Update: 06 Oct 2023
At a glance
- Drugs F 652 (Primary)
- Indications COVID-19 pneumonia
- Focus Adverse reactions
- Sponsors Evive Biotech
Most Recent Events
- 28 Sep 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 31 Jan 2022 New trial record